157 related articles for article (PubMed ID: 35188271)
21. Second primary melanomas: incidence and outcome.
Bower MR; Scoggins CR; Martin RC; Mays MP; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Noyes RD; Sussman JJ; Hagendoorn LJ; Stromberg AJ; McMasters K
Am Surg; 2010 Jul; 76(7):675-81. PubMed ID: 20698369
[TBL] [Abstract][Full Text] [Related]
22. PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma.
Marcaillou M; Linder C; Chaltiel L; Sibaud V; Pagès C; Modesto A; Chira C; Dalmasso C; Boulinguez S; Bedane C; Meyer N
Melanoma Res; 2020 Dec; 30(6):580-589. PubMed ID: 33156203
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
Afzal MZ; Shirai K
Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753
[TBL] [Abstract][Full Text] [Related]
24. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma.
Fisher NM; Schaffer JV; Berwick M; Bolognia JL
J Am Acad Dermatol; 2005 Sep; 53(3):393-406. PubMed ID: 16112344
[TBL] [Abstract][Full Text] [Related]
25. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M
J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266
[TBL] [Abstract][Full Text] [Related]
26. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
[TBL] [Abstract][Full Text] [Related]
27. Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
Verkhovskaia S; Di Pietro FR; Mastroeni S; Carbone ML; Abeni D; Morese R; Morelli FM; D'Atri S; Marchetti P; De Galitiis F; Failla CM; Fortes C
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2529-2538. PubMed ID: 34595541
[TBL] [Abstract][Full Text] [Related]
28. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
[TBL] [Abstract][Full Text] [Related]
29. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
31. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma.
Uliasz A; Lebwohl M
Int J Dermatol; 2007 Jun; 46(6):575-7. PubMed ID: 17550554
[TBL] [Abstract][Full Text] [Related]
32. Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance.
Guitera P; Menzies SW; Coates E; Azzi A; Fernandez-Penas P; Lilleyman A; Badcock C; Schmid H; Watts CG; Collgros H; Liu R; van Kemenade C; Mann GJ; Cust AE
JAMA Dermatol; 2021 May; 157(5):521-530. PubMed ID: 33729464
[TBL] [Abstract][Full Text] [Related]
33. Management of melanoma in patients with chronic lymphocytic leukemia.
Archibald WJ; Meacham PJ; Williams AM; Baran AM; Victor AI; Barr PM; Sahasrahbudhe DM; Zent CS
Leuk Res; 2018 Aug; 71():43-46. PubMed ID: 30005183
[TBL] [Abstract][Full Text] [Related]
34. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
35. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J; Cheng PF; Kaufmann C; Amann VC; Frauchiger AL; Stögner V; Held U; von Moos R; Michielin O; Braun RP; Levesque MP; Goldinger SM; Dummer R
Melanoma Res; 2017 Aug; 27(4):358-368. PubMed ID: 28509765
[TBL] [Abstract][Full Text] [Related]
36. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
38. Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
Adileh M; Yuval JB; Huang S; Shoushtari AN; Quezada-Diaz F; Pappou EP; Weiser MR; Garcia-Aguilar J; Smith JJ; Paty PB; Nash GM
Dis Colon Rectum; 2021 May; 64(5):555-562. PubMed ID: 33939387
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
40. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010.
Youlden DR; Youl PH; Soyer HP; Aitken JF; Baade PD
JAMA Dermatol; 2014 May; 150(5):526-34. PubMed ID: 25093216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
